← Oncology Approval Tracker

FDA DECISION ·

Carvykti

ciltacabtagene autoleucel · Janssen Biotech

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after at least one prior line that included a proteasome inhibitor and immunomodulatory agent, and with lenalidomide-refractory disease.

LAMPGEN ANALYSIS

Why it matters

The BCMA-directed CAR T product moved into earlier treatment after lenalidomide-refractory relapse.

What research teams should watch

Record refractory status and each prior drug class and plan referral before manufacturing and bridging timelines narrow the treatment window.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Relapsed or refractory multiple myeloma

PRIMARY RECORDS

Sources